NCT05413759 RhEumatoid Arthritis MEDIcation Adherence

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2022-06-28 with a primary completion date of 2026-12-28.

Brief Summary

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.

Eligibility Criteria

Inclusion Criteria: * Patient with diagnosed rheumatoid arthritis (RA), * Patient, male or female, aged 18 or over, * Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge * Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD), * Autonomous patient in the management of his drug treatment, * Patient understanding and speaking French, * Patient affiliated to the French general national health insurance or similar, * Patient having given his free, informed and signed consent. Exclusion Criteria: * Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study, * Patient whose regular pharmacy is currently treating another patient. * Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator), * Patient whose management of his drug treatment at home is carried out exclusively by a carer, * Patient participating in another research that may interfere (investigator's judgement) with the results of the present study, * Adult patient protected under the terms of the law (Public Health Code), * Patient not fit to carry out the follow-up, according to the judgment of the investigator, * Pregnant or breastfeeding women.

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.